4582 — SymBio Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapSucker Stock

Annual income statement for SymBio Pharmaceuticals, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,987	8,257	10,008	5,590	2,453
Cost of Revenue
Gross Profit	867	5,800	7,600	4,411	1,873
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	6,964	7,241	7,938	6,894	6,447
Operating Profit	-3,977	1,016	2,070	-1,304	-3,994
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-4,086	1,001	2,106	-1,195	-3,807
Provision for Income Taxes
Net Income After Taxes	-4,090	2,032	1,179	-1,963	-3,833
Net Income Before Extraordinary Items
Net Income	-4,090	2,032	1,179	-1,963	-3,833
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	-4,090	2,032	1,179	-1,963	-3,833
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-135	52.3	28.3	-41.2	-83.3
Dividends per Share